3-(1H-pyrazol-4-yl)pyridine allosteric modulators of the M4 muscarinic acetylcholine receptor

1. A compound of the formula I:

wherein:

X is —N═ or —C(R 8 )═;

Y is —N═ or —C(R 11 )═;

R 1 is selected from:

(1) hydrogen,

(2) halogen,

(3) —CN,

(4) —C 1-6 alkyl, which is unsubstituted or substituted with a hydroxy, pyrazolyl, dihydropyranyl, or 1-3 fluoro,

(5) —O—C 1-6 alkyl, which is unsubstituted or substituted with a hydroxy, or 1-3 fluoro,

(6) cyclopropyl,

(7) —C═CH 2 ,

(8) —C≡CH,

(9) -pyrazolyl, which is unsubstituted or substituted with —C 1-6 alkyl, and

(10) dihydropyranyl;

R 2 is selected from:

(1) hydrogen,

(2) halogen,

(3) —C 1-6 alkyl,

(4) —CN,

(5) —OC 1-6 alkyl, and

(6) —SC 1-6 alkyl;

R 3 is selected from:

(1) hydrogen,

(2) chloro,

(3) —C 1-6 alkyl, and

(4) —OC 1-6 alkyl;

R 4 is selected from:

(1) hydrogen, and

(2) fluoro;

R 5 is —C 1-6 alkyl, which is unsubstituted or substituted with:

(1) fluoro,

(2) hydroxy,

(3) —CN,

(4) keto,

(5) —C 1-6 alkyl, which is unsubstituted or substituted with hydroxy, methoxy, fluoro, or —C 1-6 alkyl-fluoro,

(6) —C 2-6 alkenyl, which is unsubstituted or substituted with fluoro,

(7) —OC 1-6 alkyl, which is unsubstituted or substituted with —C 1-6 alkyl, hydroxy, methoxy, fluoro, or —C 1-6 alkyl-fluoro,

(8) —C 3-4 cycloalkyl or C 6-10 cycloalkyl, which is unsubstituted or substituted with —C 1-6 alkyl, hydroxy, methoxy, fluoro, or —C 1-6 alkyl-fluoro,

(9) tetrahydrofuranyl, which is unsubstituted or substituted with —C 1-6 alkyl, hydroxy, methoxy, or 1-3 fluoro,

(10) tetrahydropyranyl, which is unsubstituted or substituted with —C 1-6 alkyl, hydroxy, methoxy, or 1-3 fluoro, and

(11) phenyl, which is unsubstituted or substituted with —C 1-6 alkyl, hydroxy, methoxy, or 1-3 fluoro;

each of R 8 , R 9 , R 10 and R 11 is independently selected from:

(1) hydrogen,

(2) halogen,

(3) —C 1-6 alkyl, which is unsubstituted or substituted with: hydroxy, —OC 1-6 alkyl, cyclopropyl, cyclobutyl, or 1-3 fluoro; phenyl, which is unsubstituted or substituted with hydroxy, —C 1-6 alkyl or fluoro; or pyridyl, which is unsubstituted or substituted with hydroxy, —C 1-6 alkyl or fluoro,

(4) —OC 1-6 alkyl, which is unsubstituted or substituted with a hydroxy, —OC 1-6 alkyl, cyclopropyl, cyclobutyl, or 1-3 fluoro,

(5) —C 3-6 cyclolkyl, which is unsubstituted or substituted with a hydroxy, methoxy, or 1-3 fluoro, and

(6) —CN;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 of the formula Ib:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen, R 3 is hydrogen and R 1 is selected from:

(1) hydrogen,

(2) fluoro,

(3) chloro,

(4) —CN, and

(5) methyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is —CH 2 —, which is substituted with a group selected from:

(1) adamantyl,

(2) bicyclopentyl,

(3) bicyclooctyl,

(4) cyclobutyl, which is unsubstituted or substituted with —C 1-6 alkyl or 1-3 fluoro,

(5) cyclopropyl, which is unsubstituted or substituted with —C 1-6 alkyl or 1-3 fluoro,

(6) cyclohexyl, which is unsubstituted or substituted with —C 1-6 alkyl or 1-3 fluoro,

(7) phenyl, which is unsubstituted or substituted with 1-3 fluoro;

(8) spiropentyl, and

(9) tetrahydrofuranyl, which is unsubstituted or substituted with —C 1-6 alkyl or 1-3 fluoro.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is —C 1-6 alkyl, which is unsubstituted or substituted with fluoro, —OC 1-6 alkyl, cyclopropyl, cyclobutyl, cyclohexyl, or phenyl.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 5 is —C 1-6 alkyl, which is unsubstituted or substituted with fluoro.

7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 5 is selected from:

(1) 2,2-dimethylpropyl,

(2) 2,2-difluorobutyl,

(3) 3-methylbutyl,

(4) 3-fluoro-3-methylbutyl,

(5) neopentyl,

(6) 1-(methylcyclopentyl)methyl,

(7) 1-(fluorocyclopentyl)methyl,

(8) cyclopentyl-3,3,3-trifluoro-2,2-dimethylpropyl,

(9) 1-(cyclohexylmethyl), and

(10) (1-(trifluromethyl)cyclopropyl)methyl.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of R 8 , R 9 , R 10 and R 11 is independently selected from:

(1) hydrogen,

(2) halogen,

(3) —OH,

(4) —C 1-6 alkyl, which is unsubstituted or substituted with a hydroxy, or 1-3 fluoro,

(5) —OC 1-6 alkyl, which is unsubstituted or substituted with a hydroxy, or 1-3 fluoro, and

(6) cyclopropyl.

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of R 8 , R 9 , R 10 and R 11 is independently selected from:

(1) hydrogen,

(2) fluoro,

(3) —CH 3 ,

(4) —CF 3 , and

(5) —OCH 3 , and

(6) cyclopropyl.

10. A compound which is selected from:

3-methoxy-7-(3-{1-[(1-methylcyclohexyl)methyl]-1H-pyrazol-4-yl}pyridin-2-yl)cinnoline;

7-(3-(1-(3-fluoro-3-methylbutyl)-1H-pyrazol-4-yl)-6-methylpyridin-2-yl)quinoline;

7-{3-[1-(3-fluoro-3-methylbutyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl}-3-methoxycinnoline;

7-[3-(1-benzyl-1H-pyrazol-4-yl)-6-methylpyridin-2-yl]quinoline;

7-[3-(1-benzyl-1H-pyrazol-4-yl)-6-methylpyridin-2-yl]-3-methoxycinnoline;

7-{3-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl}quinoline;

7-(6-methyl-3-{1-[(1-methylcyclohexyl)methyl]-1H-pyrazol-4-yl}pyridin-2-yl)-3-(trifluoromethyl)quinoline;

7-{3-[1-(cyclobutylmethyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl}-3-methoxycinnoline;

7-{3-[1-(bicyclo[1.1.1]pent-1-ylmethyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl}quinoline;

7-{3-[1-(bicyclo[1.1.1]pent-1-ylmethyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl}-3-methoxycinnoline;

7-{6-methyl-3-[1-(4,4,4-trifluoro-3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-(3-(1-(((3r,5r,7r)-adamantan-1-yl)methyl)-1H-pyrazol-4-yl)-6-methylpyridin-2-yl)quinoline;

7-(3-(1-(((3r,5r,7r)-adamantan-1-yl)methyl)-1H-pyrazol-4-yl)-6-methylpyridin-2-yl)-3-methoxycinnoline;

7-{3-[1-(bicyclo[2.2.2]oct-1-ylmethyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl}quinoline;

7-{3-[1-(bicyclo[2.2.2]oct-1-ylmethyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl}-3-methoxycinnoline;

7-(3-{1-[(4,4-difluorocyclohexyl)methyl]-1H-pyrazol-4-yl}-6-methylpyridin-2-yl)quinoline;

7-(3-{1-[(4,4-difluorocyclohexyl)methyl]-1H-pyrazol-4-yl}-6-methylpyridin-2-yl)-3-methoxycinnoline;

7-(3-{1-[(4-fluorocyclohexyl)methyl]-1H-pyrazol-4-yl}-6-methylpyridin-2-yl)quinoline;

7-(3-{1-[(4-fluorocyclohexyl)methyl]-1H-pyrazol-4-yl}-6-methylpyridin-2-yl)-3-methoxycinnoline;

7-{3-[1-(2-fluorobenzyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl}quinoline;

7-{3-[1-(2-fluorobenzyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl}-3-methoxycinnoline;

7-(3-{1-[(4,4-difluoro-1-methylcyclohexyl)methyl]-1H-pyrazol-4-yl}-6-methylpyridin-2-yl)-3-methoxycinnoline;

3-methoxy-7-(6-methyl-3-{1-[(2-methyltetrahydrofuran-2-yl)methyl]-1H-pyrazol-4-yl}pyridin-2-yl)cinnoline;

3-methoxy-7-[6-methyl-3-(1-[1-(trifluoromethyl)cyclobutyl]methyl 1-1H-pyrazol-4-yl)pyridin-2-yl]cinnoline;

3-methoxy-7-(6-methyl-3-[1-[(1-methylcyclobutyl)methyl]-1H-pyrazol-4-yl]pyridin-2-yl)cinnoline;

3-methoxy-7-(6-methyl-3-[1-[(1-methylcyclopropyl)methyl]-1H-pyrazol-4-yl]pyridin-2-yl)cinnoline;

5-(1-{[1-(difluoromethyl)cyclopropyl]methyl}-1H-pyrazol-4-yl)-6-quinolin-7-ylpyridine-2-carbonitrile;

5-(1-{[1-(difluoromethyl)cyclopropyl]methyl}-1H-pyrazol-4-yl)-6-(3-methoxycinnolin-7-yl)pyridine-2-carbonitrile;

6-quinolin-7-yl-5-[1-(spiro[2.2]pent-1-ylmethyl)-1H-pyrazol-4-yl]pyridine-2-carbonitrile;

7-{6-chloro-3-[1-(3-methoxy-3-methylbutyl)-1H-pyrazol-4-yl]-5-methylpyridin-2-yl}-3-methoxycinnoline;

7-{6-chloro-3-[1-(2-methoxy-2-methylpropyl)-1H-pyrazol-4-yl]-5-methylpyridin-2-yl}-3-methoxycinnoline;

6-(3-methoxycinnolin-7-yl)-5-[1-(3-methoxy-3-methylbutyl)-1H-pyrazol-4-yl]-3-methylpyridine-2-carbonitrile;

6-(3-methoxycinnolin-7-yl)-5-[1-(2-methoxy-2-methylpropyl)-1H-pyrazol-4-yl]-3-methylpyridine-2-carbonitrile;

3-methoxy-7-{3-[1-(3-methoxy-3-methylbutyl)-1H-pyrazol-4-yl]-5,6-dimethylpyridin-2-yl}cinnoline;

3-methoxy-7-{3-[1-(2-methoxy-2-methylpropyl)-1H-pyrazol-4-yl]-5,6-dimethylpyridin-2-yl}cinnoline;

7-[3-fluoro-1-(3-fluoro-3-methylbutyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl-3-methoxycinnoline;

5-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]-6-quinolin-7-ylpyridine-2-carbonitrile;

5-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]-6-(3-methoxycinnolin-7-yl)pyridine-2-carbonitrile;

5-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]-6-(2-methylquinolin-7-yl)pyridine-2-carbonitrile;

5-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]-6-(1,5-naphthyridin-3-yl)pyridine-2-carbonitrile;

5-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]-6-(3-fluoroquinolin-7-yl)pyridine-2-carbonitrile;

6-(3-chlorocinnolin-7-yl)-5-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]pyridine-2-carbonitrile;

6-cinnolin-7-yl-5-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]pyridine-2-carbonitrile;

6-quinolin-7-yl-5-(1-1 [1-(trifluoromethyl)cyclopropyl]methyl-1H-pyrazol-4-yl)pyridine-2-carbonitrile;

6-(3-methoxycinnolin-7-yl)-5-(1-1 [1-(trifluoromethyl)cyclopropyl]methyl 1-1H-pyrazol-4-yl)pyridine-2-carbonitrile;

5-[1-(2-hydroxy-3-methylbutyl)-1H-pyrazol-4-yl]-6-quinolin-7-ylpyridine-2-carbonitrile;

3-fluoro-6-quinolin-7-yl-5-(1-{[1-(trifluoromethyl)cyclopropyl]methyl}-1H-pyrazol-4-yl)pyridine-2-carbonitrile;

7-{6-methoxy-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-6-(trifluoromethyl)pyridin-2-yl}quinoline;

7-{4-methyl-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{4-methoxy-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{5-chloro-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{5-chloro-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}-3-methoxycinnoline;

7-{6-(difluoromethyl)-3-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]pyridin-2-yl}-3-methoxycinnoline;

7-{3-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]-5-fluoropyridin-2-yl}quinoline;

2-methyl-6-quinolin-7-yl-5-(1-{[1-(trifluoromethyl)cyclopropyl]methyl}-1H-pyrazol-4-ylpyridine-3-carbonitrile;

6-(3-methoxycinnolin-7-yl)-2-methyl-5-(1-{[1-(trifluoromethyl)cyclopropyl]methyl}-1H-pyrazol-4-ylpyridine-3-carbonitrile;

5-[1-(2,2-dimethylpropyl)-5-fluoro-1H-pyrazol-4-yl]-6-quinolin-7-ylpyridine-2-carbonitrile;

5-(5-fluoro-1-{[1-(trifluoromethyl)cyclopropyl]methyl}-1H-pyrazol-4-yl)-6-quinolin-7-ylpyridine-2-carbonitrile;

5-[1-(3-methyl-2-oxobutyl)-1H-pyrazol-4-yl]-6-quinolin-7-ylpyridine-2-carbonitrile;

5-[1-(2,2-difluoro-3-methylbutyl)-1H-pyrazol-4-yl]-6-quinolin-7-ylpyridine-2-carbonitrile;

2-chloro-7-{3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{6-chloro-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{4-chloro-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{6-fluoro-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

5-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-6-quinolin-7-ylpyridine-2-carbonitrile;

7-{6-(3,6-dihydro-2H-pyran-4-yl)-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-6-(1-methyl-1H-pyrazol-5-yl)pyridin-2-yl}quinoline;

7-{3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-6-propylpyridin-2-yl}quinoline;

7-{6-(cyclopropyl)-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{5-methyl-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{6-ethenyl-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{6-ethyl-3-[1(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{6-bromo-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{6-(2-methoxyethoxy)-3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{3-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-5-(methyl sulfanyl)pyridin-2-yl}quinoline;

3-methoxy-7-{6-methyl-3-[1-(4,4,4-trifluorobutyl)-1H-pyrazol-4-yl]pyridin-2-yl}cinnoline;

7-(3-{1-[(3,3-difluorocyclobutyl)methyl]-1H-pyrazol-4-yl}-6-methylpyridin-2-yl)-3-methoxycinnoline;

7-(3-{1-[2-(3,3-difluorocyclobutyl)ethyl]-1H-pyrazol-4-yl}-6-methylpyridin-2-yl)-3-methoxycinnoline;

3-methoxy-7-{6-methyl-3-[1-(4,5,5-trifluoropent-4-en-1-yl)-1H-pyrazol-4-yl]pyridin-2-yl}cinnoline;

3-methoxy-7-(6-methyl-3-{1-[2-(tetrahydrofuran-3-yl)ethyl]-1H-pyrazol-4-yl}pyridin-2-yl)cinnoline;

3-methoxy-7-{6-methyl-3-[1-(tetrahydrofuran-3-ylmethyl)-1H-pyrazol-4-yl]pyridin-2-yl}cinnoline;

3-methoxy-7-{6-methyl-3-[1-(spiro[3.3]hept-2-ylmethyl)-1H-pyrazol-4-yl]pyridin-2-yl}cinnoline;

3-{4-[2-(3-methoxycinnolin-7-yl)-6-methylpyridin-3-yl]-1H-pyrazol-1-yl}-2,2-dimethylpropanenitrile;

4-{4-[2-(3-methoxycinnolin-7-yl)-6-methylpyridin-3-yl]-1H-pyrazol-1-yl}-2,2-dimethylbutanenitrile;

7-(3-{1-[(1-fluorocyclohexyl)methyl]-1H-pyrazol-4-yl}-6-methylpyridin-2-yl)-3-methoxycinnoline;

3-methoxy-7-(6-methyl-3-{1-[(4-methyltetrahydro-2H-pyran-4-yl)methyl]-1H-pyrazol-4-yl}pyridin-2-yl)cinnoline;

6-quinolin-7-yl-5-[1-(3,3,3-trifluoro-2,2-dimethylpropyl)-1H-pyrazol-4-yl]pyridine-2-carbonitrile;

5-[1-(3,3-dimethylbutyl)-1H-pyrazol-4-yl]-6-quinolin-7-ylpyridine-2-carbonitrile;

5-[1-(3,3-difluoro-2,2-dimethylpropyl)-1H-pyrazol-4-yl]-6-quinolin-7-ylpyridine-2-carbonitrile;

6-quinolin-7-yl-5-[1-(4,4,4-trifluoro-3,3-dimethylbutyl)-1H-pyrazol-4-yl]pyridine-2-carbonitrile;

6-quinolin-7-yl-5-[1-(2,2,3,3-tetrafluoropropyl)-1H-pyrazol-4-yl]pyridine-2-carbonitrile;

7-(3-{1-[(4,4-difluoro-1-methylcyclohexyl)methyl]-1H-pyrazol-4-yl}-6-methylpyridin-2-yl)quinoline;

7-(3-{1-[(1-methylcyclohexyl)methyl]-1H-pyrazol-4-yl}pyridin-2-yl)quinoline;

7-{3-[1-(2-cyclobutylethyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{3-[1-(2-cyclopropylethyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

5-{1-[(1-methylcyclopropyl)methyl]-1H-pyrazol-4-yl}-6-quinolin-7-ylpyridine-2-carbonitrile;

3-methoxy-7-(6-methyl-3-{1-[(3-methyltetrahydrofuran-3-yl)methyl]-1H-pyrazol-4-yl}pyridin-2-yl)cinnoline;

7-(3-{1-[(2,2-dimethyl cyclopropyl)methyl]-1H-pyrazol-4-yl}-6-methylpyridin-2-yl)-3-methoxycinnoline;

7-(3-{1-[(2,2-dimethylcyclopropyl)methyl]-1H-pyrazol-4-yl}-6-methylpyridin-2-yl)quinoline;

5-{1-[(2,2-dimethylcyclopropyl)methyl]-1H-pyrazol-4-yl}-6-(3-methoxycinnolin-7-yl)pyridine-2-carbonitrile;

5-{1-[(2,2-dimethylcyclopropyl)methyl]-1H-pyrazol-4-yl}-6-quinolin-7-ylpyridine-2-carbonitrile;

5-{1-[1-(cyanomethyl)cyclopropyl]methyl-1H-pyrazol-4-yl}-6-(3-methoxycinnolin-7-yl)pyridine-2-carbonitrile;

5-{1-[1-(cyanomethyl)cyclopropyl]methyl-1H-pyrazol-4-yl}-6-quinolin-7-ylpyridine-2-carbonitrile;

7-{3-[1-(cyclohexylmethyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

7-{3-[1-(cyclohexylmethyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl}-3-methoxycinnoline;

7-{3-[1-(4,4-difluorocyclohexyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl}-3-methoxycinnoline;

7-{6-(difluoromethyl)-3-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]pyridin-2-yl}quinoline;

5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-6-quinolin-7-ylpyridine-2-carbonitrile;

5-{1-[(1-fluorocyclopropyl)methyl]-1H-pyrazol-4-yl}-6-quinolin-7-ylpyridine-2-carbonitrile;

6-(3-methoxycinnolin-7-yl)-5-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]pyridine-2-carbonitrile;

5-[1-(3-hydroxy-2,2-dimethylpropyl)-1H-pyrazol-4-yl]-6-quinolin-7-ylpyridine-2-carbonitrile;

7-{3-[1-(2-fluoro-2-methylpropyl)-1H-pyrazol-4-yl]-6-methylpyridin-2-yl}-3-methoxycinnoline;

7-{6-(difluoromethyl)-3-[1-(2-fluoro-2-methylpropyl)-1H-pyrazol-4-yl]pyridin-2-yl}-3-methoxycinnoline;

5-{1-[(1-fluorocyclobutyl)methyl]-1H-pyrazol-4-yl}-6-quinolin-7-ylpyridine-2-carbonitrile; and

5-[1-(2,2-difluoro-3-hydroxy-3-methylbutyl)-1H-pyrazol-4-yl]-6-quinolin-7-ylpyridine-2-carbonitrile;

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition which comprises an inert carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

12. A method for the treatment of a neurological and/or psychiatric disorder associated with muscarinic acetylcholine receptor dysfunction in a mammal comprising the step of administering at least one compound of claim 1 , or a pharmaceutically acceptable salt of said compound, to a patient in need thereof in an amount effective to treat said disorder.

13. The method of claim 12 , wherein the mammal has been diagnosed with a need for treatment of the disorder prior to the administering step.

14. The method of claim 12 , wherein the disorder is a neurological and/or psychiatric disorder associated with mAChR M4 dysfunction.

15. The method of claim 12 , wherein the disorder is a psychotic disorder.

16. The method of claim 15 , wherein the psychotic disorder is selected from schizophrenia, psychotic disorder, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder, delusional disorder, shared psychotic disorder, catastrophic schizophrenia, postpartum psychosis, psychotic depression, psychotic break, tardive psychosis, myxedematous psychosis, occupational psychosis, menstrual psychosis, secondary psychotic disorder, bipolar I disorder with psychotic features, and substance-induced psychotic disorder.

17. The method of claim 12 , wherein the disorder is a cognitive disorder.

18. The method of claim 17 , wherein the cognitive disorder is selected from amnesia, dementia, delirium, amnestic disorder, substance-induced persisting delirium, dementia due to HIV disease, dementia due to Huntington's disease, dementia due to Parkinson's disease, Parkinsonian-ALS dementia complex, dementia of the Alzheimer's type, age-related cognitive decline, and mild cognitive impairment.